Man Group plc Buys Shares of 94,088 Viemed Healthcare, Inc. $VMD

Man Group plc bought a new position in Viemed Healthcare, Inc. (NASDAQ:VMD) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 94,088 shares of the company’s stock, valued at approximately $1,073,000. Man Group plc owned approximately 0.25% of Viemed Healthcare as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of VMD. Raffles Associates LP bought a new position in shares of Viemed Healthcare during the 2nd quarter valued at $4,602,000. Hsbc Holdings PLC bought a new stake in Viemed Healthcare in the second quarter worth $434,000. Expect Equity LLC acquired a new position in Viemed Healthcare during the second quarter worth $2,425,000. PDT Partners LLC acquired a new position in Viemed Healthcare during the second quarter worth $268,000. Finally, Legal & General Group Plc bought a new position in Viemed Healthcare during the second quarter valued at about $97,000. Institutional investors and hedge funds own 74.24% of the company’s stock.

Viemed Healthcare Stock Up 2.0%

VMD stock opened at $8.98 on Thursday. The stock has a market capitalization of $342.05 million, a price-to-earnings ratio of 24.95, a price-to-earnings-growth ratio of 2.17 and a beta of 1.09. The company has a 50-day moving average of $10.70 and a two-hundred day moving average of $9.91. Viemed Healthcare, Inc. has a 52-week low of $6.05 and a 52-week high of $12.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.13 and a quick ratio of 1.02.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Viemed Healthcare had a return on equity of 10.16% and a net margin of 4.81%.The business had revenue of $78.10 million during the quarter, compared to the consensus estimate of $78.00 million. As a group, equities research analysts anticipate that Viemed Healthcare, Inc. will post 0.41 EPS for the current year.

Insider Buying and Selling

In other news, insider William Frazier sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.72, for a total transaction of $117,200.00. Following the completion of the transaction, the insider directly owned 73,214 shares in the company, valued at $858,068.08. The trade was a 12.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy Smokoff sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total value of $230,000.00. Following the completion of the sale, the director directly owned 75,518 shares of the company’s stock, valued at $868,457. This represents a 20.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 20.60% of the company’s stock.

Analyst Upgrades and Downgrades

VMD has been the subject of a number of analyst reports. Barrington Research began coverage on Viemed Healthcare in a research report on Monday, August 24th. They issued an “outperform” rating and a $14.00 price target for the company. Wall Street Zen downgraded Viemed Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings lowered Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Finally, Freedom Capital cut Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.00.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.